Clear Cell Sarcoma – Pipeline Insight, 2021: Featuring Key Players Tesaro, NantPharma, Rafael Pharmaceuticals and Pfizer – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Clear Cell Sarcoma – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Clear Cell Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Emerging Drugs Chapters

This segment of the Clear Cell Sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Emerging Drugs

TSR-042: Tesaro

TSR-042 is an investigational anti-programmed death (PD)-1 immunotherapy agent. It is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2. The therapy is currently under Phase II evaluation in Advanced Clear Cell Sarcoma.

CPI-613: Rafael Pharmaceuticals

CPI-613 (devimistat) is a ketoglutarate dehydrogenase complex and Pyruvate dehydrogenase complex inhibitor. These are the enzymes of TCA cycle, an indispensable process essential to tumor cell multiplication and survival, selectively in cancer cells. CPI-613 is being evaluated in Phase I clinical studies in combination with hydroxychloroquine for patients with Clear Cell Sarcoma of Soft Tissue.

Phases

This report covers around 6+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

The pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as:

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as:

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Clear Cell Sarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Clear Cell Sarcoma drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Clear Cell Sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Clear Cell Sarcoma.
• In December 2021, Rafael Pharmaceuticals announced that it partners with Sara’s Cure and SARC for the launch of Phase 2 Clinical Trial for CPI-613 (devimistat) in combination with Hydroxychloroquine for patients with Clear Cell Sarcoma of Soft Tissue.

Report Insights

• Clear Cell Sarcoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Clear Cell Sarcoma drugs?
• How many Clear Cell Sarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Clear Cell Sarcoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Clear Cell Sarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Clear Cell Sarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Tesaro
• NantPharma
• Rafael Pharmaceuticals
• Pfizer

Key Products

• TSR-042
• AMG 337
• CPI-613
• Crizotinib

Key Topics Covered:

• Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Analytical Perspective
• In-depth Commercial Assessment
• Collaboration Deals
• Mid Stage Products (Phase II)
• TSR-042: Tesaro
• Early Stage Products (Phase I)
• CPI-613: Rafael Pharmaceuticals
• Inactive Products
• Key Companies
• Key Products
• Unmet Needs
• Market Drivers and Barriers
• Future Perspectives and Conclusion
• Analyst Views
• Key Companies

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/tbfwv6

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900